There are currently no approved medicines that treat the underlying cause of PKD.
However, Agios Pharmaceuticals has launched a clinical trial called “DRIVE PK Trial”.
This is a phase 2 clinical trial for for the oral medication, AG-348, This therapy has been developed as a potential treatment for Pyruvate Kinase (PK) deficiency.
The study is being conducted to determine whether AG-348 increases the levels of healthy red blood cells in the body. Trial locations are open at several sites across the USA, as well as in Canada, Italy, and the UK. To learn more about this study visit Agios’ Drive PK Trial website.
Disclaimer: This article is written by patients and is meant for basic informational purposes only. It is not intended to serve as medical advice, substitute for a doctor's appointment or to be used for diagnosing or treating a disease. Users of this website are advised to consult with their physician before making any decisions concerning their health. For details see our full disclaimer.